Transdermal Hormone Therapy for VMS and Cardiovascular Risk Management

This episode, titled "Transdermal Hormone Therapy for VMS and Cardiovascular Risk Management," features panelists examining the cardiovascular risk assessment and hormonal treatment considerations for a 54-year-old African American woman presenting with VMS and multiple metabolic risk factors. The experts note that while her quantitative cardiovascular risk scores are currently low, her clinical picture warrants careful attention given SWAN data showing that African American women tend to experience more severe and longer-lasting VMS, as well as her elevated risk for metabolic syndrome, prediabetes, and future cardiovascular disease. The panel emphasizes that now — before active cardiovascular disease develops — is the optimal window for intervention, noting that hot flashes themselves are not trivial and have been linked to endothelial injury, small vascular disease, and inflammation.

The discussion then turns to the selection of transdermal estradiol with micronized progesterone as the preferred hormonal approach for this patient. The experts explain that transdermal delivery bypasses hepatic first-pass metabolism, thereby reducing the risk of venous thromboembolism — a meaningful consideration given the patient's BMI. While oral estrogen is not contraindicated and may offer some lipid panel benefits, the experts agree that transdermal therapy represents the safer starting point for this patient's profile. The panel also acknowledges practical considerations such as cost, adhesive allergies, and medication availability that may influence route of administration in real-world clinical settings.

Throughout the discussion, the experts reinforce the importance of shared decision making and encourage patients to trust and report their bodily experiences as valuable clinical data, framing menopause care as an ongoing, evolving journey rather than a one-time treatment decision.

In the next episode, "Shared Decision Making and MHT Safety in Women with VMS," panelists will discuss how to address patient hesitations around menopause hormone therapy, including overcoming mistrust rooted in WHI misinformation, setting realistic expectations for onset of action, and navigating cardiovascular risk stratification to guide appropriate treatment and referral decisions.